Avenue Therapeutics effects 1-for-75 reverse stock split to meet Nasdaq bid price rule

AVENUE THERAPEUTICS, INC.

Reverse split effective April 26, 2024; shares reduced from ~44.7M to ~0.6M.
Split is to bring Company into compliance with Nasdaq $1.00 minimum bid price.
No fractional shares; fraction holders get rounded up to next whole share.
Ticker remains ATXI; new CUSIP 05360L403. VStock Transfer is exchange agent.
Holders via brokers need no action; physical certificate holders will receive instructions.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

AVENUE THERAPEUTICS, INC.: Filed Certificate of Amendment to effect a 1-for-75 reverse stock split of common stock (effective 2024-04-26).

Change: charter amendment
Effective: 2024-04-26

Exact text from the filing

On April 25, 2024, Avenue Therapeutics, Inc. (the “ Company ”) filed a Certificate of Amendment to its Third Amended and Restated Certificate of Incorporation (the “ Amendment ”) with the Secretary of State of the State of Delaware to effect a 1-for-75 reverse stock split

View on SEC.gov

Browse all governance changes →

AVENUE THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-013436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.